Outcomes of Triple-Negative Breast Cancers (TNBC) Compared with Non-TNBC: Does the Survival Vary for All Stages?

World Journal of Surgery

Volumn 40, Issue 6, 2016, Pages 1362-1372

  Agarwal, Gaurav ^a   Nanda, Gitika ^a   Lal, Punita ^a   Mishra, Anjali ^a   Agarwal, Amit ^a   Agrawal, Vinita ^a   Krishnani, Narendra ^a  

^a SANJAY GANDHI POSTGRADUATE INSTITUTE OF MEDICAL SCIENCES   (India)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR; TUMOR MARKER;

ADULT; AGE; AGED; BREAST NEOPLASMS; CANCER GRADING; CANCER STAGING; COHORT ANALYSIS; FEMALE; HUMAN; KAPLAN MEIER METHOD; METABOLISM; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; PATHOLOGY; PROGNOSIS; RETROSPECTIVE STUDY; TREATMENT OUTCOME; TRIPLE NEGATIVE BREAST NEOPLASMS;

ADULT; AGE FACTORS; AGED; BIOMARKERS, TUMOR; BREAST NEOPLASMS; COHORT STUDIES; COMBINED MODALITY THERAPY; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM STAGING; PROGNOSIS; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; TRIPLE NEGATIVE BREAST NEOPLASMS;

EID: 84957598268     PISSN: 03642313     EISSN: 14322323     Source Type: Journal    
DOI: 10.1007/s00268-016-3422-4     Document Type: Article

References (26)

1. Hammond ME, Hayes DF, Dowsett M et al (2010) American Society of Clinical Oncology/College Of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. J Clin Oncol 28(16):2784-2795
2. Goldhirsch A, Wood WC, Coates AS et al (2011) Strategies for subtypes-dealing with the diversity of breast cancer: highlights of the St. Gallen international expert consensus on the primary therapy of early breast cancer 2011. Ann Oncol 22(8):1736-1747
3. Hamm C, El-Masri M, Poliquin G et al (2011) A single-centre chart review exploring the adjusted association between breast cancer phenotype and prognosis. Curr Oncol 18(4):191-196
4. Kaplan HG, Malmgren JA (2008) Impact of triple negative phenotype on breast cancer prognosis. Breast J 14(5):456-463
5. Carey LA, Dees EC, Sawyer L et al (2007) The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes. Clin Cancer Res 13(8):2329-2334
6. Lee JA, Kim KI, Bae JW et al (2010) Korean Breast Cancer Society. Triple negative breast cancer in Korea-distinct biology with different impact of prognostic factors on survival. Breast Cancer Res Treat 123(1):177-187
7. Lin NU, Vanderplas A, Hughes ME et al (2012) Clinicopathologic features, patterns of recurrence, and survival among women with triple-negative breast cancer in the National Comprehensive Cancer Network. Cancer 118(22):5463-5472
8. Leong SP, Shen ZZ, Liu TJ et al (2010) Is breast cancer the same disease in Asian and Western countries? World J Surg 34(10):2308-2324. doi: 10.1007/s00268-010-0683-1
9. Agarwal G, Pradeep PV, Aggarwal V et al (2007) Spectrum of breast cancer in Asian women. World J Surg 31(5):1031-1040. doi: 10.1007/s00268-005-0585-9
10. Ram Prabu MP, Raina V, Shukla NK et al (2011) A study of triple-negative breast cancer at a cancer institute in India. J Clin Oncol 29:(suppl; abstr e11548)
11. Shet T, Agrawal A, Nadkarni M et al (2009) Hormone receptors over the last 8 years in a cancer referral center in India: what was and what is? Indian J Pathol Microbiol 52(2):171-174
12. Kuraparthy S, Reddy KM, Yadagiri LA et al (2007) Epidemiology and patterns of care for invasive breast carcinoma at a community hospital in Southern India. World J Surg Oncol. 23(5):56
13. Dey S, Boffetta P, Mathews A et al (2009) Risk factors according to estrogen receptor status of breast cancer patients in Trivandrum, South India. Int J Cancer 125(7):1663-1670
14. Carey LA, Perou CM, Livasy CA et al (2006) Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA 295(21):2492-2502
15. Millikan RC, Newman B, Tse CK et al (2008) Epidemiology of basal-like breast cancer. Breast Cancer Res Treat 109(1):123-139
16. Bauer KR, Brown M, Cress RD et al (2007) Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype: a population-based study from the California cancer Registry. Cancer 109(9):1721-1728
17. Matos I, Dufloth R, Alvarenga M et al (2005) p63, cytokeratin 5 and P-cadherin: three molecular markers to distinguish basal phenotype in breast carcinomas. Virchows Arch 447(4):688-694
18. Elnashar AT, Ali el-SM, Gaber A (2012) The prognostic value of triple negative in stage II/III breast cancer. J Oncol Pharm Pract. 18(1):68-75
19. Park YH, Lee SJ, Cho EY et al (2011) Clinical relevance of TNM staging system according to breast cancer subtypes. Ann Oncol 22(7):1554-1560
20. Ring AE, Smith IE, Ashley S et al (2004) Oestrogen receptor status, pathological complete response and prognosis in patients receiving neoadjuvant chemotherapy for early breast cancer. Brit J Cancer 91:2012-2017
21. Martin M, Romero A, Cheang MC et al (2011) Genomic predictors of response to doxorubicin versus docetaxel in primary breast cancer. Breast Cancer Res Treat 128(1):127-136
22. Liedtke C, Mazouni C, Hess KR et al (2008) Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer. J Clin Oncol 26(8):1275-1281
23. Sørlie T, Perou CM, Tibshirani R et al (2001) Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA 98(19):10869-10874
24. Gianni L, Zambetti M, Clark K et al (2005) Gene expression profiles in paraffin-embedded core biopsy tissue predict response to chemotherapy in women with locally advanced breast cancer. J Clin Oncol 23(29):7265-7277
25. Onitilo AA, Engel JM, Greenlee RT, Mukesh BN (2009) Breast cancer subtypes based on ER/PR and Her2 expression: comparison of clinicopathologic features and survival. Clin Med Res. 7(1-2):4-13
26. Pogoda K, Niwikska A, Murawska M, Pieńkowski T (2013) Analysis of pattern, time and risk factors influencing recurrence in triple-negative breast cancer patients. Med Oncol 30(1):388